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Aqueous humor (AH) supports avascular tissues in the anterior segment of the eye, maintains intraocular pressure, and
potentially influences the pathogenesis of ocular diseases. Nevertheless, the AH proteome is still poorly defined despite
several previous efforts, which were hindered by interfering high abundance proteins, inadequate animal models, and
limited proteomic technologies. To facilitate future investigations into AH function, the AH proteome was extensively
characterized using an advanced proteomic approach. Samples from patients undergoing cataract surgery were pooled
and depleted of interfering abundant proteins and thereby divided into two fractions: albumin-bound and albumin-depleted.
Multidimensional Protein Identification Technology (MudPIT) was utilized for each fraction; this incorporates strong
cation exchange chromatography to reduce sample complexity before reversed-phase liquid chromatography and tandem
mass spectrometric analysis. Twelve proteins had multi-peptide, high confidence identifications in the albumin-bound
fraction and 50 proteins had multi-peptide, high confidence identifications in the albumin-depleted fraction. Gene
ontological analyses were performed to determine which cellular components and functions were enriched. Many proteins
were previously identified in the AH and for several their potential role in the AH has been investigated; however, the
majority of identified proteins were novel and only speculative roles can be suggested. The AH was abundant in anti-
oxidant and immunoregulatory proteins as well as anti-angiogenic proteins, which may be involved in maintaining the
avascular tissues. This is the first known report to extensively characterize and describe the human AH proteome and lays
the foundation for future work regarding its function in homeostatic and pathologic states.
The aqueous humor (AH) is a clear fluid that fills the
anterior segment of the eye and bathes the lens, iris, and
corneal endothelium [1]. It is secreted by the ciliary body and
functions  to  provide  nutrients  and  remove  waste  from
avascular tissues [2], as well as create the intraocular pressure
that maintains the convex shape of the cornea. The AH has
antioxidant properties and purported immune response roles
during  inflammation  and  infection  [3,4].  However,  the
proteins that are responsible for carrying out these functions
are largely unknown. The protein content of the AH has been
studied extensively [5-12]; however, due to limitations in
technology, an extensive and definitive description of human
AH proteins has yet to be provided. Furthermore, proteins in
the AH are thought to be involved in development of several
eye diseases [13,14], and investigating the AH proteome will
facilitate generation of new hypotheses regarding the etiology
of  such  pathologies.  Thus  our  goal  in  this  study  was  to
investigate  the  AH  proteome  and  determine  its  protein
constituents  with  high  confidence  using  an  advanced
proteomic approach.
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Center for Pediatric Research, Cancer Research Institute, 1044 W.
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Previous AH proteomic studies were limited by a number
of  factors  including  interfering  high  abundance  proteins,
inadequate  animal  models,  and  limited  proteomic
technologies.  In  1998  Rohde  et  al.  [5]  used  a  proteomic
approach to analyze AH proteins but because of technological
limitations, proteins were identified based solely on molecular
weight and thus must be considered tentative. In 2005 Funding
et  al.  [15]  and  in  2008  Duan  et  al.  [16]  each  used  two-
dimensional  electrophoresis  in  combination  with  tandem
mass spectrometry to identify seven unique AH proteins with
high confidence, and in each study interfering high abundance
proteins such as albumin limited the depth of the analysis.
Also, in 2007 Stastna et al. [1] used an elaborate combination
of proteomic techniques to identify almost a hundred proteins
from rabbit AH; however, the rabbit genome is incomplete so
tentative cross-species identifications had to be made using a
broad mammalian database. Here we employed an albumin/
IgG depletion strategy to remove these interfering abundant
proteins in human derived AH, thus yielding two fractions:
albumin-bound  and  albumin-depleted.  For  each  fraction,
Multidimensional  Protein  Identification  Technology
(MudPIT) was utilized, which incorporates two-dimensional
liquid  chromatography  coupled  with  tandem  mass
spectrometry  (2D-LC-MS/MS).  In  the  first  liquid
chromatography dimension, peptides are separated by strong
cation exchange chromatography thereby reducing sample
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2740complexity  before  separation  in  the  second  dimension,
standard  reversed-phase  high  performance  liquid
chromatography. In the final step, data are collected using
tandem  mass  spectrometric  analysis.  This  led  to  an
unprecedented high number of definitive human AH protein
identifications.
METHODS
The  study  subjects  were  patients  who  were  scheduled  to
undergo standard cataract surgery at a tertiary referral center,
Price Vision Group (Indianapolis, IN). Exclusion criteria were
as  follows:  previous  intraocular  surgery,  history  of
conjunctivitis or any ocular infection within the previous 3
months, intraocular inflammation, or any eye disease. An
independent Institutional review board (IRB) approved the
study and all subjects signed a written Informed Consent
document. Before undergoing cataract surgery, the patient's
eye  was  anesthetized  topically  with  proparacaine.  A  stab
incision was made in the peripheral cornea, and 0.1 to 0.2 ml
of anterior chamber fluid was aspirated using a 30-gauge
needle. Aqueous humor samples were stored frozen in liquid
nitrogen until analysis. A single surgeon (F.W.P.) collected
all the samples. Any sample suspected of being contaminated
with blood or iris pigment was discarded. Samples from 12
subjects were analyzed; 50% were from females, mean age
was 65±6.3 years, 11 were Caucasian, and 1 was Asian (Table
1).
The  following  sample  preparation  and  mass
spectrometric  analyses  were  carried  out  at  Monarch
LifeSciences (Indianapolis, IN). All reagents and chemicals
were purchased from Sigma-Aldrich (St. Louis, MO) unless
indicated  otherwise.  AH  samples  were  pooled  and
fractionated into bound and flow-through (depleted) fractions
using Sigma-Aldrich ProteoPrep Immunoaffinity Albumin &
IgG  Depletion  Kit.  The  fractionation  was  performed  via
manufacturer’s  procedures.  Protein  concentration  for  each
fraction was determined by the BCA protein concentration
assay  (Bio-Rad,  Hercules,  CA).  The  albumin-depleted
fraction contained 116 µg, and the albumin-bound fraction
contained 221 µg of protein. Each fraction was denatured with
8 M urea, reduced with 10 mM dithiothreitol (DTT), and
alkylated with 55 mM iodoacetamide. Urea concentration was
lowered to 1.6 M with 10 mM Ammonium bicarbonate (pH
8). Trypsin (V5280; Promega, Madison, WI) was prepared by
adding 100 µl of ice cold 0.1 M ammonium bicarbonate to the
trypsin vial to make a 1µg/µl solution, then added in a 1:20
(trypsin:protein)  ratio  and  incubated  overnight  at  37  °C.
Peptides (100 µl) were precipitated with 800 µl of diethylether
and 400 µl of methanol to remove salt. Then, each sample was
dissolved in 0.1% formic acid, and 40 µg of protein digest was
loaded onto SCX column (Zorbax, Bio-SCXII 35 x 0.3 mm,
3.5 µm) at 3 µl/min with an Agilent 1100 high pressure liquid
chromatography  (HPLC)  system  (Agilent  Technologies,
Santa Clara, CA). Peptides were eluted with a 2.5 mM to 250
mM NaCl gradient for 2 hr collecting fractions every 8 min,
thus  yielding  16  fractions  by  strong  cation  exchange
chromatography.  Each  of  these  16  fractions  for  both  the
albumin-bound and albumin-depleted fractions was dried and
resuspended in 40 µl of 0.1% formic acid. Columns were
equilibrated with 3% acetonitrile (ACN) and fractions were
loaded onto the trapping column at 5 µl/min. Salt was washed
away for 15 min with 3% ACN before peptides were injected
onto the C18-reversed-phase column. Zorbax C18 (300 Ǻ, 3.5
µm;  Agilent  Technologies)  resin  was  used  for  both  the
trapping column (200 µm×2 cm, 5 µm) and the analytical
column (100 µm×10 cm, 5 µm) and were self-packed in house.
Peptides were eluted with a linear gradient from 5 to 45%
ACN over 120 min at room temperature, at a flow rate of 500
nl/min, and the effluent was electro-sprayed into the LTQ
mass spectrometer (Thermo-Fisher Scientific, Waltham, MA)
TABLE 1. PATIENT DATA.
Age Sex Race Contact lens Surgical history
63 F Caucasian No Lasik
57 F Caucasian No Anterior lamellar keratoplasty
59 F Caucasian No NA
68 M Caucasian No NA
72 M Caucasian No NA
74 M Caucasian No NA
60 F Caucasian No Lasik
59 M Asian Yes NA
70 F Caucasian No NA
65 M Caucasian Yes Lasik
62 F Caucasian Yes NA
75 M Caucasian No NA
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2741with a nanospray source. The source was operated in positive
ion mode with 3.0 kV electrospray potential, a sheath gas flow
of 15 arbitrary units, and a capillary temperature of 200 °C.
The source lenses were set by maximizing the ion current for
the 2+ charge state of angiotensin. Data were collected in the
triple play mode. Maximum ion time was 200 msec for the
full scan and 500 msec for the zoom scan and the MS/MS scan.
The acquired data were filtered by a proprietary algorithm
that was developed by Higgs, et al. [17] and described in detail
in a recent publication. Database searches were carried out
using both Sequest (Thermo-Fisher Scientific, Waltham, MA)
and X!Tandem algorithms and the human protein database
from IPI (version 3.48). Parameters were set as follows: a
mass tolerance of 2 Da for precursors and 0.7 Da for fragment
ions,  two  missed  cleavage  sites  allowed  for  trypsin,
carbamidomethyl  cysteine  as  fixed  modification,  and
oxidized methionine as optional modification. The q-value
represents peptide false identification rate and was calculated
by  a  recently  published  method  [18]  which  incorporates
Sequest and X!Tandem results in addition to a number of other
relevant factors such as Δ [M+H]+ and charge state. Protein
identifications  were  assigned  to  one  of  four  groups  as
discussed previously [19] with priority 1 identifications (IDs)
regarded as high-confidence and requiring ≥2 unique peptides
and a q-value ≤0.1. Priority 2 IDs require only a single unique
sequence and a q-value ≤0.1. Priority 3 and 4 IDs require
multiple or single unique peptides, respectively, and peptide
q-values  fall  in  the  range  of  0.25-0.1.  Gene  ontological
analyses were carried out using Princeton University’s gene
ontology (GO) tools available at. The Swiss-Prot accession
numbers listed in Table 2 and Table 3 were used as the input
values  with  the  “Generic  GO  Term  Finder”  tool.  The
“goa_human”  gene  association  file  was  used  for  both
“function” and “component” analyses.
RESULTS
A  statistical  summary  provided  in  Table  4  indicates  the
number of proteins identified at each priority level from each
fraction collected. The twelve albumin-bound AH proteins
identified with high confidence (priority 1) are listed in Table
2, and the fifty AH proteins identified with high confidence
(priority 1) in the albumin-depleted (flow-through) fraction
are listed in Table 3. Eight of the proteins were common to
both  fractions;  therefore,  in  total  we  identified  54  unique
human AH proteins in this study. Only the proteins meeting
priority 1 criteria (multiple unique peptides with a minimum
q-value ≤0.1) were chosen to list in this manuscript as most
experts  agree  that  protein  identities  established  by  less
stringent criteria are questionable [20]. Proteins identified at
priority levels 2-4 can be found in Appendix 1. The Swiss-
Prot protein accession number, protein common name, and
molecular  weight  are  provided  in  Table  2  and  Table  3.
Identified proteins were cross-referenced with Anderson et
al.’s [21] published list of plasma proteome constituents, and
their presence in the plasma is listed in the table as present or
not found. Over 80% of the proteins identified in each fraction
were previously identified as plasma proteins by Anderson et
al. [21]. Also listed are the protein’s molecular weight (kDa),
the number of unique peptides identified by MS/MS for each
protein, each protein’s minimum peptide q-value, and the
peptide sequence corresponding to the peptide with the lowest
q-value.
A representative tandem mass spectrum corresponding to
a peptide (FDEFFSEGCAPGSK) of the protein transferrin is
illustrated in Figure 1. The high mass accuracy measurements
of the fragmented peptides’ characteristic b and y ions enabled
high confidence matching and contributed to its low q-value.
Gene ontological analyses for function and component GO
terms were performed, and the results are illustrated in Figure
2. This analysis revealed an enrichment for extracellular space
proteins and proteins typically found in lipoprotein particles,
as well as for proteins with functions in lipid binding and
endopeptidase inhibition.
DISCUSSION
Rather than focus on differentially expressed proteins in the
AH of patients with a particular ocular pathology, we chose
to concentrate our efforts on a thorough investigation of the
human AH proteome isolated from patients who did not have
any significant health problems other than cataracts, which are
just part of the normal aging process. We utilized albumin
depletion  to  remove  the  known  interfering  high  abundant
protein and associated proteins and therefore increase lower
abundant protein identification. We also incorporated 2D-LC-
MS/MS  to  further  fractionate  samples  and  facilitate
identification of lower abundant proteins. By doing so, we
were able to overcome obstacles of previous AH proteome
analyses and provide the highest confidence information to
date on the protein composition of healthy human aqueous
humor in a population of aged adult subjects.
Historical context: In 1998 Rohde et al. [5] attempted to
tentatively  identify  lower  abundance  human  AH  proteins
using  membrane  preconcentration  coupled  with  capillary
electrophoresis and mass spectrometry (mPC-CE-MS). Of the
27 putative protein identifications, the following seven were
confirmed  in  our  analysis:  beta-2  microglobulin,  an  S100
calcium  binding  protein,  hemoglobin,  Cystatin  C,  and
apolipoprotein A-I as well as albumin and IgG. As the authors
astutely noted, protein identification based only on molecular
weight  (MW)  can  only  be  considered  tentative  until
confirmatory evidence, such as amino acid sequence, can be
provided as we have done here.
In  2005,  Funding  et  al.  [15]  used  two-dimensional
electrophoresis (2-DE) to separate AH proteins and image
analysis to determine differentially expressed AH proteins in
patients  with  acute  corneal  rejection.  Then  using  a
combination  of  immunoblotting,  matrix-assisted  laser
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2744desorption/ionization-time of flight (MALDI-TOF MS), and
nanoLC-MS/MS they were able to identify six proteins with
high confidence: cytokeratin type II, clusterin (apolipoprotein
J), serine protease inhibitor, albumin, alpha-1-antitrypsin, and
transthyretin. We did not confirm the presence of cytokeratin,
a common protein contaminant in mass spectrometric protein
identifications, and we also did not identify serine protease
inhibitor specifically, but did identify proteins from the serine
protease  inhibitor  (SERPIN)  family  such  as  alpha-1-
antichymotrypsin and antithrombin III. The presence of the
other four AH proteins were confirmed in our analysis.
In  2007,  Stastna  et  al.  [1]  employed  an  elegant
combination  of  1-DE,  2-DE,  and  reversed  phase  liquid
chromatography (RPLC) for protein separation and MALDI-
TOF MS and LC-MS/MS for AH protein identification. This
appears to be the only publication dealing exclusively with the
AH proteome, rather than a differential expression analysis,
and is thus the most relevant published report of an extensive
TABLE 4. STATISTICAL SUMMARY OF PROTEIN IDENTIFICATION RESULTS FROM THE LC-MS/MS EXPERIMENT IN BOTH ALBUMIN-DEPLETED AND ALBUMIN-
BOUND GROUPS.
Albumin-depleted                                   Albumin-bound
Protein
Priority
Peptide ID
Confidence
Multiple
Sequences
Median Number
of Sequences
Number of
Proteins
Median Number
of Sequences
Number of
Proteins
1 HIGH YES 5 50 3 12
2 HIGH NO 1 35 1 92
3 MODERATE YES 2 2 2 3
4 MODERATE NO 1 74 1 94
Figure  1.  Transferrin  peptide  tandem
mass spectra Tandem mass spectrum of
the peptide FDEFFSEGCAPGSK from
the  protein  Transferrin  (above).  This
peptide  was  identified  with  high
confidence through the matching of the
experimental and theoretical m/z values
(below)  from  the  peptides’
characteristic b and y ions (delta m/z
<0.1).
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2745characterization of the proteome. The major limitation to their
approach, however, was the use of a rabbit model for AH
analysis. Only 34 of their 98 proteins were identified as rabbit
(O. cuniculus) proteins with the rest being identified as other
various mammalian proteins. This limited the analysis for two
reasons: 1) the rabbit is not always useful as a model of human
ocular pathology; for example the rabbit corneal endothelium
regenerates  unlike  that  in  humans  [22],  and  2)  the  rabbit
genome is currently incomplete, so one must rely upon other
mammalian genomes for cross-species identifications, which
must  be  regarded  as  tentative  until  the  rabbit  gene(s)
sequence(s) can be confirmed. Thus, the next clear step in AH
analysis was an extensive investigation of the human AH
proteome. We could only confirm 21 of the 98 rabbit AH
protein identifications reported by Stastna et al. [1] in the
human AH. These proteins are highlighted in Table 2 and
Table 3 with the exception of the following six proteins which
were  identified  outside  of  priority  1  (priority  2-4,  less
confident  identifications):  type  II  collagen,  desmocollin,
desmoglein,  plasminogen,  cathepsin,  and  retinol-binding
protein.
In  2008  Duan  et  al.  [16]  used  2-DE  to  determine
differentially expressed protein spots in the AH of patients
with  myopia.  They  determined  the  identities  of  six
differentially expressed protein spots with high confidence
using  LC-MS/MS.  Four  of  these  spots  were  identified  as
albumin with the other two being transthyretin and vitamin D-
binding  protein,  which  we  also  identified  with  high
confidence. Thus, albumin clearly interfered with identifying
more proteins in the studies of Duan et al. [16] and Funding
et  al.  [15],  and  this  highlighted  the  importance  of  the
prefractionation step we utilized to deplete interfering high
abundance proteins such as albumin and IgG.
Biological context: Gene ontological analyses performed
using the “Generic GO Term Finder” tool for function and
component GO terms revealed several interesting findings.
The  component  analysis  revealed  that  almost  half  of  the
proteins identified were predicted to be extracellular space
proteins and that proteins associated with several different
lipoprotein particles were present in the AH, the relevance of
which  is  discussed  below.  Regarding  function,  many  AH
proteins were found to be involved in lipid transport and
binding and in endopeptidase inhibition. A manual search of
the literature detailed below has revealed a potential role for
several of these proteins in a variety of physiological functions
of AH, many of which were identified for the first time here.
Lipoproteins  in  the  AH  are  thought  to  provide  a
significant source of lipids for avascular tissues such as the
lens in which de novo cholesterol synthesis is considered
insufficient to meet even 50% of its total cholesterol need
[23,24]. We identified apolipoprotein J (Apo J), also known
as clusterin, which has been suggested to enter the AH from
corneal endothelium. Apo J is thought to play a role in cell
membrane  maintenance  at  tissue-fluid  interfaces  possibly
protecting cells from complement factors in addition to having
speculated immunological roles [25], so it is plausible that
Apo J may have a similar function in the AH. It is one of seven
lipoprotein  proteins  identified  in  this  study.  Interestingly,
lipoproteins are also involved in lysophosphatidic acid (LPA)
transport. LPA is a phospholipid that is present in the AH and
known to modulate a number of cellular responses. Another
LPA transport protein identified in this study is Gelsolin,
which  also  has  proposed  anti-oxidant  properties  [26].
Alpha-2-glycoprotein,  zinc  (ZAG),  which  has  proposed
immunoregulatory roles, is also proposed to bind fatty acids
and regulate lipid metabolism [27]. The interphotoreceptor
retinoid-binding protein and transthyretin identified in this
study  also  have  roles  in  fatty  acid  transport  and  lipid
metabolism, respectively [28,29], yet their specific roles in the
aqueous humor remains unclear. Another identified protein,
Figure 2. Function and component gene
ontological  analyses  of  proteins
identified in the aqueous humor. Each
bar represents the percent of priority 1
AH proteins (a sum of unique proteins
in the albumin-depleted and albumin-
bound  fractions)  that  belong  to  a
particular GO term listed on y-axis.
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2746vitamin D-binding protein (DBP), was previously speculated
to have a role in the AH and is a multi-functional plasma
protein known to transport vitamin D metabolites and bind
fatty  acids  as  well  as  modulate  immunological  processes
[30]. DBP has been found to be associated with certain ocular
pathologies  [16].  Other  lipoproteins  are  speculated  to  be
involved in ocular pathological processes as well including
age-related macular degeneration (AMD) [31].
The roles of several other proteins identified here have
already been purported in the AH. For example, though the
exact role of Glutathione Peroxidase in the AH is unclear, it
is known to protect cells and other proteins from oxidative
damage and most likely serves a similar function in the AH
[32]. Prostaglandin-H2 D-isomerase is thought to be involved
in maintenance of intraocular pressure as well as development
and  maintenance  of  the  blood-aqueous  barrier  [33].
Antithrombin III, a protease inhibitor, has been suggested to
regulate intraocular pressure by influencing the function of
the trabecular meshwork [34]. Alpha-1-antitrypsin, a serine
protease inhibitor, has been proposed to protect the cornea
from  degradation  by  neutrophil  elastase  released  during
inflammation [35]. Cystatin C, a cysteine protease inhibitor,
has been found to be secreted by the ciliary body into the AH
of rat and mouse eyes at very high concentrations indicating
it would bind essentially all cysteine proteases that may leak
into the AH [36]. It is reasonable that other protease inhibitors
identified here such as alpha-2-macroglobulin (A2M) and
alpha-1-antichymotrypsin  1  and  2  could  play  similarly
important  roles.  Moreover,  many  proteases  and  protease
inhibitors are thought to be secreted by the ciliary epithelium,
indicating that they could have a specific purpose in the AH
[37].  Interestingly,  A2M  can  inhibit  proteases  such  as
Cathepsin D, which we identified at a priority 2 level (not
shown).  Cathepsin  D  is  known  to  degrade  Fibulin-1,  a
potentially important anti-angiogenic protein [38], which we
also identified. Thus, A2M may play an important role in
protecting the cornea by inhibiting Cathepsin D. Importantly,
Cystatin  C  is  also  an  anti-angiogenic  protein  [39]  as  is
Fibulin-3,  also  known  as  EGF-containing  fibulin-like
extracellular matrix protein 1 [40].
Anti-angiogenic proteins are key molecules in the AH as
there  are  several  tissues  that  must  remain  avascular  to
maintain their function such as the cornea which serves as a
“clear window” to the eye. Indeed, it is known that the AH
suppresses  angiogenesis  [41],  but  the  exact  proteins
responsible remain incompletely understood. We identified a
number of proteins with high confidence, some for the first
time  in  the  AH,  that  have  also  been  identified  as  potent
inhibitors  of  angiogenesis.  These  include  DBP,  Beta-2-
glycoprotein  1,  Collagen  alpha-1(IV),  and  Pigment
epithelium-derived factor (PEDF) [42-45]. DBP is modified
by  membrane-bound  β-galactosidase  and  sialidase  of
activated B- and T-lymphocytes, and the resultant molecule
is known as DBP-maf (macrophages activating factor), which
is a key anti-angiogenic protein [46]. PEDF has been shown
to  inhibit  endothelial  cell  migration  in  the  presence  of
angiogenic  proteins  such  as  VEGF,  and  inhibits
neovascularization of the rat cornea [45]. Its expression in the
AH has been associated with lens opacity as well as total anti-
oxidant capacity [47]. PEDF levels are inversely correlated
with age, and lack of PEDF has been proposed to play a role
in  the  development  of  cataracts  [48].  Other  AH  proteins
identified  here  that  were  previously  found  to  be  anti-
angiogenic elsewhere include Histidine-rich glycoprotein and
Opticin [49,50].
Conclusion:  In  this  study,  we  employed  multiple
prefractionation techniques and tandem mass spectrometry to
identify lower abundant proteins and extensively characterize
the  human  AH  proteome.  These  multi-peptide,  high-
confidence, priority 1 proteins, widely regarded as definitive
identifications,  provide  a  reliable  foundation  and  should
enable  the  generation  of  new  hypotheses  regarding
pathologies of the eye as well as normal AH function. Though
these IDs should be considered definitive, it is still possible
that  there  were  AH  proteins  not  identified  with  high
confidence in this study. Proteins identified at priority levels
2-4 could be considered candidates for future investigation in
this  regard.  The  exact  number  of  human  AH  proteins  is
unknown, and it is possible that tens if not hundreds of lower
abundance proteins exist in the AH and many of these could
fall below current detection limits. Nevertheless, based on
previous investigations of AH and other body fluids, the AH
would not be expected to contain as many proteins as a typical
cell lysate. Other areas for future study include determining
differences in AH protein levels between patients in different
age  groups  with  different  ocular  pathologies,  as  well  as
differences between men and women; aspects that could not
be addressed in the current study.
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